T Delaunoit
Overview
Explore the profile of T Delaunoit including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
244
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Demols A, Borbath I, Van Den Eynde M, Houbiers G, Peeters M, Marechal R, et al.
Ann Oncol
. 2020 May;
31(9):1169-1177.
PMID: 32464280
Background: There is a high unmet clinical need for treatments of advanced/metastatic biliary tract cancers after progression on first-line chemotherapy. Regorafenib has demonstrated efficacy in some gastrointestinal tumors that progress...
2.
Elez E, Hendlisz A, Delaunoit T, Sastre J, Cervantes A, Varea R, et al.
Br J Cancer
. 2016 Jan;
114(4):372-80.
PMID: 26766738
Background: This single-arm phase II study investigated the EGFR monoclonal antibody necitumumab plus modified FOLFOX6 (mFOLFOX6) in first-line treatment of locally advanced or metastatic colorectal cancer (mCRC). Methods: Patients received...
3.
Lemaire J, Delaunoit T, Molle G
Acta Chir Belg
. 2014 Apr;
114(1):79-81.
PMID: 24720145
A sixty years-old patient was admitted with a gastric tumor corresponding to an adenocarcinoma developed in ectopic pancreatic tissue. Hundred cases of gastric heterotopic pancreas are shown in literature. This...
4.
Borbath I, Ceratti A, Verslype C, Demols A, Delaunoit T, Laurent S, et al.
Ann Oncol
. 2013 Aug;
24(11):2824-9.
PMID: 23975665
Background: Cholangiocarcinomas are uncommon tumours with a poor prognosis, that frequently present epidermal growth factor receptor overexpression. Methods: In a multi-centre phase II trial, patients with unresectable cholangiocarcinoma, naïve to...
5.
Delaunoit T, Peny M, Mignon M, Dili A
Acta Gastroenterol Belg
. 2012 May;
75(1):3-4.
PMID: 22567739
Spleen metastases from solid tumours are rather exceptional, especially for those located in the digestive tract. Although these lesions are usually associated with multivisceral disease at terminal stage, several cases...
6.
Marechal R, Vos B, Polus M, Delaunoit T, Peeters M, Demetter P, et al.
Ann Oncol
. 2011 Nov;
23(6):1525-30.
PMID: 22039087
Background: Induction chemotherapy has been suggested to impact on preoperative chemoradiation efficacy in locally advanced rectal cancer (LARC). To evaluate in LARC patients, the feasibility and efficacy of a short...
7.
Delaunoit T, Peny M, Mignon M, Dili A
Acta Gastroenterol Belg
. 2011 May;
74(1):99-100.
PMID: 21563664
No abstract available.
8.
Hublet A, Wijtenburg E, Lismonde M, Thomas T, Majois F, de Lovinfosse S, et al.
Acta Chir Belg
. 2010 Aug;
110(3):267-71.
PMID: 20690505
Aim: To assess the feasibility of percutaneous pulmonary radiofrequency ablation (RFA) executed by a single surgeon. Materials And Methods: Between 2007 and 2010, 15 procedures were performed in 11 patients...
9.
Verset G, Borbath I, Delaunoit T, Demetter P, Demolin G, Hendlisz A, et al.
Acta Gastroenterol Belg
. 2009 May;
72(1):59-62.
PMID: 19402374
The management of gastro-entero-pancreatic neuroendocrine tumours is evolving thanks to new TNM-classification, diagnostic and staging procedures and new therapeutic options. Targeting new pathways, mostly angiogenesis, development of novel agents is...
10.
Verslype C, Carton S, Borbath I, Delaunoit T, Demetter P, Demolin G, et al.
Acta Gastroenterol Belg
. 2009 May;
72(1):54-8.
PMID: 19402373
Somatostatin analogs (SSAs) have an important role in the management of patients with neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP NETs). These compounds can control the symptoms induced...